13 30

Cited 0 times in

Comparison of long-term outcomes of infliximab vs. adalimumab as treatment for ulcerative colitis in biologic-naive patients

Other Titles
 생물학적 제제 사용력이 없는 실제 임상 궤양성 대장염 환자군을 대상으로 한 인플릭시맵과 아달리무맙의 장기 비교 
Authors
 이용일 
College
 College of Medicine (의과대학) 
Department
 Department of Medicine 
Degree
석사
Issue Date
2020
Abstract
Background/Aim: Tumor necrosis factor (TNF)-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no head-to-head comparison of the treatment efficacy and outcomes between the two agents. The aim of this study was to compare the efficacy and long-term outcomes of infliximab vs. adalimumab in biologic-naïve patients with UC. Methods: We retrospectively analyzed the records of 113 biologic-naïve patients with UC who received between September 2012 and December 2017. We compared remission and response rates between groups at 8 and 52 weeks. We used Kaplan-Meier curves to compare long term outcomes and logistic regression analysis and Cox-proportional hazard regression models to assess factors affecting outcomes. Results: The median follow-up duration was 25.8 months. Baseline clinical characteristics were similar between groups. There were no significant differences between the two groups in the rates of clinical remission and clinical response at 8 and 52 weeks. Multivariate analyses showed long term outcomes, including all-cause hospitalization, UC-related hospitalization, corticosteroid prescription, discontinuation of TNF-α inhibitor therapy, and switching to a secondary TNF-α inhibitor were not significantly different between groups. Elevated C-reactive protein level (more than 5 mg/L) was a significant predictive factor for poor outcomes. During the follow-up period, the rates of adverse event were not statistically different between the two groups. There were no cases of discontinuation of treatment because of adverse event. Conclusion: Infliximab and adalimumab have similar treatment efficacy and long-term outcomes in biologic-naïve patients with moderate to severe UC.
Files in This Item:
TA02462.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Others (기타) > 2. Thesis
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/181153
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links